Výsledky vyhledávání

Akademický článek

'De-escalation' strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany

Autor: van Engen A, Casamayor M, Kim S, Watt M, Odeyemi I

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 9, Pp 763-774 (2017)

Anke van Engen,1 Montserrat Casamayor,2 Soyoung Kim,3 Maureen Watt,4 Isaac Odeyemi4 1Quintiles Consulting, Hoofddorp, the Netherlands; 2Quintiles Consulting, Barcelona, Spain; 3Astellas Pharma Singapore Pte., Singapore; 4Astellas Pharma Inc., Chertse

Externí odkaz: https://doaj.org/article/45188635b9c14e1da25ab0bd3dac672d

Zobrazit plný text záznamu

Akademický článek

Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients

Autor: Muduma G, Shupo FC, Dam S, Hawken NA, Aballéa S, Odeyemi I, Toumi M

Publikováno v: Patient Preference and Adherence, Vol 2016, Iss Issue 1, Pp 27-36 (2016)

Gorden Muduma,1 Francis C Shupo,2 Sophie Dam,3 Natalia A Hawken,3 Samuel Aballéa,3 Isaac Odeyemi,1 Mondher Toumi4 1Astellas Pharma Europe Ltd, Chertsey, 2Creativ-Ceutical Ltd, London, UK; 3Creativ-Ceutical Ltd, Paris, 4Public Health (EA 3279), Facul

Externí odkaz: https://doaj.org/article/36e4e6be82d148f6a0637f9220435b69

Zobrazit plný text záznamu

Akademický článek

Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales

Autor: Muduma G, Shaw J, Hart WM, Odeyemi A, Odeyemi I

Publikováno v: Patient Preference and Adherence, Vol 2014, Iss default, Pp 1537-1546 (2014)

Gorden Muduma,1 Jane Shaw,2 Warren M Hart,3 Abayomi Odeyemi,3 Isaac Odeyemi21Astellas Pharma Europe Limited, Chertsey, UK; 2Astellas Pharma Limited, Chertsey, UK; 3EcoStat Consulting UK Limited, London, UKBackground: End-stage renal disease is the ir

Externí odkaz: https://doaj.org/article/c0680909085043cf931a7d4d80313c5b

Zobrazit plný text záznamu

Akademický článek

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence

Autor: Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF

Publikováno v: Patient Preference and Adherence, Vol 2014, Iss default, Pp 391-399 (2014)

Gorden Muduma,1 Isaac Odeyemi,1 Jayne Smith-Palmer,2 Richard F Pollock21Astellas Pharma Europe, Chertsey, UK; 2Ossian Health Economics and Communications, Basel, SwitzerlandBackground and aims: Advagraf is a once-daily prolonged-release formulation o

Externí odkaz: https://doaj.org/article/2deae2c626574e8db3fa98b266a9f168

Zobrazit plný text záznamu

Akademický článek

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation

Autor: Wex J, Sidhu M, Odeyemi I, Abou-Setta AM, Retsa P, Tombal B

Publikováno v: ClinicoEconomics and Outcomes Research, Vol 2013, Iss default, Pp 257-269 (2013)

Jaro Wex,1 Manpreet Sidhu,2 Isaac Odeyemi,2 Ahmed M Abou-Setta,1 Peny Retsa,2 Bertrand Tombal31PharmArchitecture Limited, London, UK; 2Astellas Pharma Europe Ltd, Chertsey, UK; 3Cliniques Universitaires Saint-Luc, Brussels, BelgiumObjective: Leuproli

Externí odkaz: https://doaj.org/article/285c7ea870034074a602811b34f3bf4d

Zobrazit plný text záznamu